New England Journal of Medicine has highlighted the ARISTOTLE trial as 'one of the most practice changing and lifesaving papers from the past 19 years'. The selection by Editor in Chief Jeffrey Drazen highlighted the research which found apixaban superior to warfarin in reducing stroke and systemic embolism in patients with AF, with a better bleeding profile as one of the 12 most important stroke papers submitted to the NEJM in two decades.
You can download the entire article DRAZEN’S DOZEN: ARTICLES THAT CHANGED PRACTICE SINCE 2000 here.
Achieving our vision of a life free from stroke is a task that WSO cannot achieve alone. We are committed to building our partnerships at the global, regional and national level to scale up and deliver improvements in prevention, treatment and support to reduce the burden of stroke.